ABSTRACT
In this study, we aimed to evaluate the changes in laboratory parameters of COVID-19 hospitalized patients who admitted to the intensive care unit (ICU). In this retrospective study, the confirmed cases of COVID-19 patients who were hospitalized in ward and ICU from 19 January 2020 to 27 February 2020 in Firoozgar hospital, Tehran, Iran were enrolled. We analyzed clinical characteristics and laboratory findings through medical records. SPSS v.25 was used for statistical analysis. The 70 COVID-19 patients by the mean age±std. deviation 68.37±13.29 years (range 27-93 years) were carried out. The average duration of hospitalization±std. deviation was 7.4±6.17 days (7-27 days). 43 cases were male (61.4%). Fifteen patients (21.4%) did not have any underlying disease. There was significant increasing in laboratory parameters included white blood cells (p<0.0001), Creatinine (p = 0.007), aspartate aminotransferase (AST) (p = 0.050) and alanine transaminase (ALT) (p = 0.031). However, lymphocyte count was significantly decreased during hospitalization in ward before ICU-admission (p<0.0001). There was no significant difference for platelets count (p = 0.94), lactate dehydrogenase (p = 0.36), International Normalized Ratio (INR) (p = 0.114) and Partial Thromboplastin Time (PTT) (p = 0.72). Most ICU-admitted patients presented with respiratory syndrome characteristics. ICU-admitted patients had significant increase in WBC and decrease in lymphocyte count. Evidence of failure in kidney, liver function, higher activity of the coagulation system were discovered among ICU-admitted patients.
ABSTRACT
Methods: In this review, the aim was to disease prevention and control methods and Chinachr('39')s experiences in this field. For these purposes, keywords such as coronavirus, novel coronavirus, SARS-CoV-2, acute respiratory syndrome, 2019-nCoV, prevention and control were searched in popular databases including PubMed, Google Scholar, Science Direct and Scopus. Databases related to COVID-19 to access new articles have also been used by some of the top journals in the field, including JAMA, Lancet, Cell, Nature, BMJ and medRxiv.
ABSTRACT
Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [COVID-19] quickly turned into a pandemic. Gastrointestinal involvement, especially liver diseases, is one of the main complications of COVID-19 patients. Objectives: The current study aimed to evaluate the high incidence of liver involvement in COVID-19 hospitalized patients and its association with mortality. Methods: A total of 560 hospitalized patients with a confirmed diagnosis of COVID-19 were included. Death was considered as the outcome. In addition to liver enzymes, demographic, clinical, and other laboratory data were also collected. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels_ 40 were considered as abnormal. To investigate the association between abnormal levels of liver enzymes and death, multiple regression logistic was used. Results: According to the findings, 29.1% (95% CI = 25.3% - 32.9%) of patients had high levels (_ 40 IU) of ALT, and 45.1% (95% CI = 40.9% - 49.3%) had high levels of AST (_ 40 IU). The frequency (based on %) of high levels of AST (_ 40 U/liter) was significantly higher in patients who died [67.3% (95% CI = 54.5% - 80.1%] of COVID-19 than those who survived [44.9% (95% CI = 39.7% - 50.0%)] (Pvalue < 0.001). No significant difference was detected in ALT between expired [29.1% (95% CI = 16.7% - 41.5%)] and survived patients [30.7% (95% CI = 25.9% - 35.5%] (P-value = 0.791). AST was found to have an independent association with death in multiple logistic regression (Wald = 4.429, OR (95% CI) = 1.014 (1.008 - 1.020), P-value = 0.035). Conclusions: Liver involvement is a common finding in COVID-19 hospitalized patients. Higher levels of AST were significantly associated with an increased mortality rate in COVID-19 patients.
ABSTRACT
In late December, 2019, a novel coronavirus was first reported in Wuhan, named as SARS-CoV-2 caused a series of acute atypical respiratory diseases. To date, virus has infected >9 million people and almost 630,193 death that is estimated about 6% it mainly transmitted through contaminated respiratory droplets between people. So far, many hypotheses have been put forward about how the virus originated but here on theory about the origin of the virus as a result of mutation and natural selection will be discussed. Right now there is not enough information to make sure that weather recovery from COVID-19 is safe or immunity does provide long-term protection against COVID-19. The persistence of the virus has been investigated at various surfaces. Many companies are trying to make a vaccine for this virus, so that, the Moderna American company has been able to get the approval of three phases of making the vaccine. In this review we tried to introduce the SARS-CoV-2 and review the preventive instructions and related literature.